Form 4: Ionis Pharmaceuticals Director Joseph Wender Acquires Shares Through RSU Vesting

Ionis Pharmaceuticals Director Joseph H. Wender acquired 4,079 shares of common stock on July 15, 2025, through the vesting of Restricted Stock Units.

Summary

• Joseph H. Wender, a Director of Ionis Pharmaceuticals Inc., acquired 4,079 shares of common stock.
• The acquisition occurred on July 15, 2025.
• The shares were acquired pursuant to the vesting and release of a Restricted Stock Unit (RSU) award.
• Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• Following this transaction, Joseph H. Wender beneficially owns 136,835 shares of common stock indirectly through a Trust.
• The Restricted Stock Units vest 100% on either the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and are delivered on the July 15th following the vesting date.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director through RSU vesting is a routine compensation event. While not a direct open market purchase, it increases insider ownership, which is generally viewed as a neutral to slightly positive signal of alignment with shareholder interests.

Positives

• Increased insider ownership: A director acquiring shares, even through vesting, can be seen as a positive signal of alignment with shareholder interests.

Future Outlook

Not applicable as this document is a report of an insider transaction and does not provide forward-looking statements or guidance.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Joseph H. Wender, a Director of Ionis Pharmaceuticals Inc., acquired shares from the company through the vesting of Restricted Stock Units, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction increases the beneficial ownership of a director, potentially signaling continued alignment of interests between management and shareholders.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Insider Transaction, Joseph H. Wender, Restricted Stock Unit, RSU, Common Stock, Director, Beneficial Ownership